What is Sermorelin?
Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). Unlike exogenous GH administration, sermorelin works upstream by prompting the pituitary gland to produce and release its own growth hormone. Researchers have studied it as a tool to explore age-related GH decline and pituitary responsiveness. Because it preserves the hypothalamic-pituitary feedback axis, it is considered a physiologically conservative approach in GH research.
Mechanism of action
Sermorelin binds the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary, triggering cyclic AMP-mediated GH synthesis and secretion. Its very short half-life (~10–20 minutes) means it produces discrete GH pulses that mimic natural secretion rather than sustained elevation, allowing normal feedback inhibition to remain intact.
Researched benefits
- Stimulation of endogenous pituitary GH release in pulsatile, physiologic patterns
- Increases in IGF-1 levels observed in clinical studies of GH-deficient adults
- Improvements in sleep architecture and slow-wave sleep in research subjects
- Lean body mass support and modest fat reduction in longer-term protocols
- Preservation of hypothalamic-pituitary-axis feedback compared to exogenous GH
Researched dosage
Most research protocols use 100–500 mcg administered 1× per day via subcutaneous injection. Research protocols typically administer 100–500 mcg subcutaneously once daily at bedtime to align with the natural nocturnal GH surge. Fasting prior to injection is recommended in most protocols to avoid blunting of the GH pulse.
A typical cycle runs 12 weeks on, then 4 weeks off before reassessment.
Use the calculator below to convert your target Sermorelin dose into exact insulin-syringe units.
Reconstitution & storage
A standard 2 mg vial reconstituted with 2 mL of bacteriostatic water yields 1000 mcg/mL. Store lyophilized vials at 2–8°C. Once reconstituted, refrigerate and use within 30 days. Protect from light and freezing.
Side effects & considerations
- Transient facial flushing or warmth at injection site
- Mild headache shortly after administration
- Injection-site redness or mild swelling
- Occasional nausea reported in early dosing
Sermorelin stacks
- GHRH + GHRP Synergy — paired with Ipamorelin. Amplified, clean pituitary GH pulse. Researchers frequently pair Sermorelin with Ipamorelin to exploit the synergistic relationship between GHRH and ghrelin-receptor agonism, producing larger GH pulses than either alone without elevating cortisol or prolactin.
- Recovery & Composition — paired with BPC-157. Combined tissue healing and GH axis support. Some protocols pair Sermorelin's GH-stimulating action with BPC-157's local tissue repair signaling in recovery-focused research models.
Selected research
- Sermorelin: a synthetic peptide for the diagnosis and treatment of GH deficiency — Expert Opinion on Drug Metabolism & Toxicology, 2007
- Growth hormone-releasing hormone and sleep — Hormone Research, 1998
- Effects of growth hormone-releasing hormone on body composition in healthy older adults — Annals of Internal Medicine, 2008